Research ArticleAccepted Article
Development and initial validation of a lupus-specific measure of extent of and reasons for medication nonadherence
Kai Sun, Theresa M. Coles, Corrine I. Voils, D. Ryan Anderson, Amanda Eudy, Rebecca E. Sadun, Jennifer L. Rogers, Lisa G. Criscione-Schreiber, Jayanth Doss, Mithu Maheswaranathan and Megan Clowse
The Journal of Rheumatology September 2022, jrheum.220399; DOI: https://doi.org/10.3899/jrheum.220399
Kai Sun
K Sun, MD, MS, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; TM Coles, PhD, Assistant Professor, Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; CI Voils, PhD, Professor, William S Middleton Memorial Veterans Hospital and Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; DR Anderson, MD, PhD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; AE Eudy, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA;RE Sadun, MD, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; JL Rogers, MD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; LG Criscione-Schreiber, MD, MEd, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; J Doss, MD, MPH, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; M Maheswaranathan, MD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; MEB Clowse, MD, MPH, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Research reported in this publication was supported by the Duke Center for REsearch to AdvanCe Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities (U54MD012530), and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH 1KL2TR002554). Dr. Coles receives research funding from FDA (75F40119C10080, 75F40120C00069), Pfizer, Merck (Q-11859), NIH (5R01-CA249568-02), PCORI (HL-2019C1-16059), the Duke Endowment, and a private donation, and consults with Regenxbio. Dr. Voils is supported by a Research Career Scientist award (RCS 14-443) from the Health Services Research & Development service of the Department of Veterans Affairs (VA). Dr. Eudy receives research funding from NIH NCATS Award Number 1KL2TR002554, Pfizer, and Exagen. Dr. Rogers receives research funding from GSK, Pfizer, and Exagen, and consults for Eli Lilly, Immunovant, and Exagen. Dr. Clowse receives research funding from GSK, Exagen, and Pfizer, and consults for GSK and UCB. Dr. Doss receives research funding from Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the VA, or the United States Government. Corresponding author: Kai Sun, MD MS Address: DUMC 2978, Durham, NC 27710. Email: kai.sun@duke.edu
Theresa M. Coles
K Sun, MD, MS, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; TM Coles, PhD, Assistant Professor, Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; CI Voils, PhD, Professor, William S Middleton Memorial Veterans Hospital and Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; DR Anderson, MD, PhD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; AE Eudy, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA;RE Sadun, MD, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; JL Rogers, MD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; LG Criscione-Schreiber, MD, MEd, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; J Doss, MD, MPH, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; M Maheswaranathan, MD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; MEB Clowse, MD, MPH, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Research reported in this publication was supported by the Duke Center for REsearch to AdvanCe Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities (U54MD012530), and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH 1KL2TR002554). Dr. Coles receives research funding from FDA (75F40119C10080, 75F40120C00069), Pfizer, Merck (Q-11859), NIH (5R01-CA249568-02), PCORI (HL-2019C1-16059), the Duke Endowment, and a private donation, and consults with Regenxbio. Dr. Voils is supported by a Research Career Scientist award (RCS 14-443) from the Health Services Research & Development service of the Department of Veterans Affairs (VA). Dr. Eudy receives research funding from NIH NCATS Award Number 1KL2TR002554, Pfizer, and Exagen. Dr. Rogers receives research funding from GSK, Pfizer, and Exagen, and consults for Eli Lilly, Immunovant, and Exagen. Dr. Clowse receives research funding from GSK, Exagen, and Pfizer, and consults for GSK and UCB. Dr. Doss receives research funding from Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the VA, or the United States Government. Corresponding author: Kai Sun, MD MS Address: DUMC 2978, Durham, NC 27710. Email: kai.sun@duke.edu
Corrine I. Voils
K Sun, MD, MS, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; TM Coles, PhD, Assistant Professor, Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; CI Voils, PhD, Professor, William S Middleton Memorial Veterans Hospital and Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; DR Anderson, MD, PhD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; AE Eudy, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA;RE Sadun, MD, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; JL Rogers, MD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; LG Criscione-Schreiber, MD, MEd, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; J Doss, MD, MPH, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; M Maheswaranathan, MD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; MEB Clowse, MD, MPH, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Research reported in this publication was supported by the Duke Center for REsearch to AdvanCe Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities (U54MD012530), and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH 1KL2TR002554). Dr. Coles receives research funding from FDA (75F40119C10080, 75F40120C00069), Pfizer, Merck (Q-11859), NIH (5R01-CA249568-02), PCORI (HL-2019C1-16059), the Duke Endowment, and a private donation, and consults with Regenxbio. Dr. Voils is supported by a Research Career Scientist award (RCS 14-443) from the Health Services Research & Development service of the Department of Veterans Affairs (VA). Dr. Eudy receives research funding from NIH NCATS Award Number 1KL2TR002554, Pfizer, and Exagen. Dr. Rogers receives research funding from GSK, Pfizer, and Exagen, and consults for Eli Lilly, Immunovant, and Exagen. Dr. Clowse receives research funding from GSK, Exagen, and Pfizer, and consults for GSK and UCB. Dr. Doss receives research funding from Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the VA, or the United States Government. Corresponding author: Kai Sun, MD MS Address: DUMC 2978, Durham, NC 27710. Email: kai.sun@duke.edu
D. Ryan Anderson
K Sun, MD, MS, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; TM Coles, PhD, Assistant Professor, Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; CI Voils, PhD, Professor, William S Middleton Memorial Veterans Hospital and Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; DR Anderson, MD, PhD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; AE Eudy, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA;RE Sadun, MD, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; JL Rogers, MD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; LG Criscione-Schreiber, MD, MEd, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; J Doss, MD, MPH, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; M Maheswaranathan, MD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; MEB Clowse, MD, MPH, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Research reported in this publication was supported by the Duke Center for REsearch to AdvanCe Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities (U54MD012530), and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH 1KL2TR002554). Dr. Coles receives research funding from FDA (75F40119C10080, 75F40120C00069), Pfizer, Merck (Q-11859), NIH (5R01-CA249568-02), PCORI (HL-2019C1-16059), the Duke Endowment, and a private donation, and consults with Regenxbio. Dr. Voils is supported by a Research Career Scientist award (RCS 14-443) from the Health Services Research & Development service of the Department of Veterans Affairs (VA). Dr. Eudy receives research funding from NIH NCATS Award Number 1KL2TR002554, Pfizer, and Exagen. Dr. Rogers receives research funding from GSK, Pfizer, and Exagen, and consults for Eli Lilly, Immunovant, and Exagen. Dr. Clowse receives research funding from GSK, Exagen, and Pfizer, and consults for GSK and UCB. Dr. Doss receives research funding from Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the VA, or the United States Government. Corresponding author: Kai Sun, MD MS Address: DUMC 2978, Durham, NC 27710. Email: kai.sun@duke.edu
Amanda Eudy
K Sun, MD, MS, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; TM Coles, PhD, Assistant Professor, Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; CI Voils, PhD, Professor, William S Middleton Memorial Veterans Hospital and Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; DR Anderson, MD, PhD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; AE Eudy, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA;RE Sadun, MD, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; JL Rogers, MD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; LG Criscione-Schreiber, MD, MEd, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; J Doss, MD, MPH, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; M Maheswaranathan, MD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; MEB Clowse, MD, MPH, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Research reported in this publication was supported by the Duke Center for REsearch to AdvanCe Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities (U54MD012530), and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH 1KL2TR002554). Dr. Coles receives research funding from FDA (75F40119C10080, 75F40120C00069), Pfizer, Merck (Q-11859), NIH (5R01-CA249568-02), PCORI (HL-2019C1-16059), the Duke Endowment, and a private donation, and consults with Regenxbio. Dr. Voils is supported by a Research Career Scientist award (RCS 14-443) from the Health Services Research & Development service of the Department of Veterans Affairs (VA). Dr. Eudy receives research funding from NIH NCATS Award Number 1KL2TR002554, Pfizer, and Exagen. Dr. Rogers receives research funding from GSK, Pfizer, and Exagen, and consults for Eli Lilly, Immunovant, and Exagen. Dr. Clowse receives research funding from GSK, Exagen, and Pfizer, and consults for GSK and UCB. Dr. Doss receives research funding from Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the VA, or the United States Government. Corresponding author: Kai Sun, MD MS Address: DUMC 2978, Durham, NC 27710. Email: kai.sun@duke.edu
Rebecca E. Sadun
K Sun, MD, MS, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; TM Coles, PhD, Assistant Professor, Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; CI Voils, PhD, Professor, William S Middleton Memorial Veterans Hospital and Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; DR Anderson, MD, PhD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; AE Eudy, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA;RE Sadun, MD, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; JL Rogers, MD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; LG Criscione-Schreiber, MD, MEd, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; J Doss, MD, MPH, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; M Maheswaranathan, MD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; MEB Clowse, MD, MPH, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Research reported in this publication was supported by the Duke Center for REsearch to AdvanCe Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities (U54MD012530), and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH 1KL2TR002554). Dr. Coles receives research funding from FDA (75F40119C10080, 75F40120C00069), Pfizer, Merck (Q-11859), NIH (5R01-CA249568-02), PCORI (HL-2019C1-16059), the Duke Endowment, and a private donation, and consults with Regenxbio. Dr. Voils is supported by a Research Career Scientist award (RCS 14-443) from the Health Services Research & Development service of the Department of Veterans Affairs (VA). Dr. Eudy receives research funding from NIH NCATS Award Number 1KL2TR002554, Pfizer, and Exagen. Dr. Rogers receives research funding from GSK, Pfizer, and Exagen, and consults for Eli Lilly, Immunovant, and Exagen. Dr. Clowse receives research funding from GSK, Exagen, and Pfizer, and consults for GSK and UCB. Dr. Doss receives research funding from Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the VA, or the United States Government. Corresponding author: Kai Sun, MD MS Address: DUMC 2978, Durham, NC 27710. Email: kai.sun@duke.edu
Jennifer L. Rogers
K Sun, MD, MS, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; TM Coles, PhD, Assistant Professor, Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; CI Voils, PhD, Professor, William S Middleton Memorial Veterans Hospital and Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; DR Anderson, MD, PhD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; AE Eudy, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA;RE Sadun, MD, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; JL Rogers, MD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; LG Criscione-Schreiber, MD, MEd, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; J Doss, MD, MPH, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; M Maheswaranathan, MD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; MEB Clowse, MD, MPH, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Research reported in this publication was supported by the Duke Center for REsearch to AdvanCe Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities (U54MD012530), and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH 1KL2TR002554). Dr. Coles receives research funding from FDA (75F40119C10080, 75F40120C00069), Pfizer, Merck (Q-11859), NIH (5R01-CA249568-02), PCORI (HL-2019C1-16059), the Duke Endowment, and a private donation, and consults with Regenxbio. Dr. Voils is supported by a Research Career Scientist award (RCS 14-443) from the Health Services Research & Development service of the Department of Veterans Affairs (VA). Dr. Eudy receives research funding from NIH NCATS Award Number 1KL2TR002554, Pfizer, and Exagen. Dr. Rogers receives research funding from GSK, Pfizer, and Exagen, and consults for Eli Lilly, Immunovant, and Exagen. Dr. Clowse receives research funding from GSK, Exagen, and Pfizer, and consults for GSK and UCB. Dr. Doss receives research funding from Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the VA, or the United States Government. Corresponding author: Kai Sun, MD MS Address: DUMC 2978, Durham, NC 27710. Email: kai.sun@duke.edu
Lisa G. Criscione-Schreiber
K Sun, MD, MS, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; TM Coles, PhD, Assistant Professor, Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; CI Voils, PhD, Professor, William S Middleton Memorial Veterans Hospital and Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; DR Anderson, MD, PhD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; AE Eudy, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA;RE Sadun, MD, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; JL Rogers, MD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; LG Criscione-Schreiber, MD, MEd, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; J Doss, MD, MPH, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; M Maheswaranathan, MD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; MEB Clowse, MD, MPH, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Research reported in this publication was supported by the Duke Center for REsearch to AdvanCe Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities (U54MD012530), and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH 1KL2TR002554). Dr. Coles receives research funding from FDA (75F40119C10080, 75F40120C00069), Pfizer, Merck (Q-11859), NIH (5R01-CA249568-02), PCORI (HL-2019C1-16059), the Duke Endowment, and a private donation, and consults with Regenxbio. Dr. Voils is supported by a Research Career Scientist award (RCS 14-443) from the Health Services Research & Development service of the Department of Veterans Affairs (VA). Dr. Eudy receives research funding from NIH NCATS Award Number 1KL2TR002554, Pfizer, and Exagen. Dr. Rogers receives research funding from GSK, Pfizer, and Exagen, and consults for Eli Lilly, Immunovant, and Exagen. Dr. Clowse receives research funding from GSK, Exagen, and Pfizer, and consults for GSK and UCB. Dr. Doss receives research funding from Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the VA, or the United States Government. Corresponding author: Kai Sun, MD MS Address: DUMC 2978, Durham, NC 27710. Email: kai.sun@duke.edu
Jayanth Doss
K Sun, MD, MS, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; TM Coles, PhD, Assistant Professor, Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; CI Voils, PhD, Professor, William S Middleton Memorial Veterans Hospital and Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; DR Anderson, MD, PhD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; AE Eudy, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA;RE Sadun, MD, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; JL Rogers, MD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; LG Criscione-Schreiber, MD, MEd, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; J Doss, MD, MPH, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; M Maheswaranathan, MD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; MEB Clowse, MD, MPH, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Research reported in this publication was supported by the Duke Center for REsearch to AdvanCe Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities (U54MD012530), and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH 1KL2TR002554). Dr. Coles receives research funding from FDA (75F40119C10080, 75F40120C00069), Pfizer, Merck (Q-11859), NIH (5R01-CA249568-02), PCORI (HL-2019C1-16059), the Duke Endowment, and a private donation, and consults with Regenxbio. Dr. Voils is supported by a Research Career Scientist award (RCS 14-443) from the Health Services Research & Development service of the Department of Veterans Affairs (VA). Dr. Eudy receives research funding from NIH NCATS Award Number 1KL2TR002554, Pfizer, and Exagen. Dr. Rogers receives research funding from GSK, Pfizer, and Exagen, and consults for Eli Lilly, Immunovant, and Exagen. Dr. Clowse receives research funding from GSK, Exagen, and Pfizer, and consults for GSK and UCB. Dr. Doss receives research funding from Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the VA, or the United States Government. Corresponding author: Kai Sun, MD MS Address: DUMC 2978, Durham, NC 27710. Email: kai.sun@duke.edu
Mithu Maheswaranathan
K Sun, MD, MS, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; TM Coles, PhD, Assistant Professor, Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; CI Voils, PhD, Professor, William S Middleton Memorial Veterans Hospital and Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; DR Anderson, MD, PhD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; AE Eudy, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA;RE Sadun, MD, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; JL Rogers, MD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; LG Criscione-Schreiber, MD, MEd, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; J Doss, MD, MPH, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; M Maheswaranathan, MD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; MEB Clowse, MD, MPH, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Research reported in this publication was supported by the Duke Center for REsearch to AdvanCe Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities (U54MD012530), and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH 1KL2TR002554). Dr. Coles receives research funding from FDA (75F40119C10080, 75F40120C00069), Pfizer, Merck (Q-11859), NIH (5R01-CA249568-02), PCORI (HL-2019C1-16059), the Duke Endowment, and a private donation, and consults with Regenxbio. Dr. Voils is supported by a Research Career Scientist award (RCS 14-443) from the Health Services Research & Development service of the Department of Veterans Affairs (VA). Dr. Eudy receives research funding from NIH NCATS Award Number 1KL2TR002554, Pfizer, and Exagen. Dr. Rogers receives research funding from GSK, Pfizer, and Exagen, and consults for Eli Lilly, Immunovant, and Exagen. Dr. Clowse receives research funding from GSK, Exagen, and Pfizer, and consults for GSK and UCB. Dr. Doss receives research funding from Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the VA, or the United States Government. Corresponding author: Kai Sun, MD MS Address: DUMC 2978, Durham, NC 27710. Email: kai.sun@duke.edu
Megan Clowse
K Sun, MD, MS, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; TM Coles, PhD, Assistant Professor, Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; CI Voils, PhD, Professor, William S Middleton Memorial Veterans Hospital and Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; DR Anderson, MD, PhD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; AE Eudy, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA;RE Sadun, MD, PhD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; JL Rogers, MD, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; LG Criscione-Schreiber, MD, MEd, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; J Doss, MD, MPH, Assistant Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; M Maheswaranathan, MD, Medical Instructor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA; MEB Clowse, MD, MPH, Associate Professor, Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Research reported in this publication was supported by the Duke Center for REsearch to AdvanCe Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities (U54MD012530), and National Center for Advancing Translational Sciences of the National Institutes of Health (NIH 1KL2TR002554). Dr. Coles receives research funding from FDA (75F40119C10080, 75F40120C00069), Pfizer, Merck (Q-11859), NIH (5R01-CA249568-02), PCORI (HL-2019C1-16059), the Duke Endowment, and a private donation, and consults with Regenxbio. Dr. Voils is supported by a Research Career Scientist award (RCS 14-443) from the Health Services Research & Development service of the Department of Veterans Affairs (VA). Dr. Eudy receives research funding from NIH NCATS Award Number 1KL2TR002554, Pfizer, and Exagen. Dr. Rogers receives research funding from GSK, Pfizer, and Exagen, and consults for Eli Lilly, Immunovant, and Exagen. Dr. Clowse receives research funding from GSK, Exagen, and Pfizer, and consults for GSK and UCB. Dr. Doss receives research funding from Pfizer. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the VA, or the United States Government. Corresponding author: Kai Sun, MD MS Address: DUMC 2978, Durham, NC 27710. Email: kai.sun@duke.edu
Article Figures & Data
Additional Files
Data Suppl
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Development and initial validation of a lupus-specific measure of extent of and reasons for medication nonadherence
Kai Sun, Theresa M. Coles, Corrine I. Voils, D. Ryan Anderson, Amanda Eudy, Rebecca E. Sadun, Jennifer L. Rogers, Lisa G. Criscione-Schreiber, Jayanth Doss, Mithu Maheswaranathan, Megan Clowse
The Journal of Rheumatology Sep 2022, jrheum.220399; DOI: 10.3899/jrheum.220399
Accepted manuscript
Development and initial validation of a lupus-specific measure of extent of and reasons for medication nonadherence
Kai Sun, Theresa M. Coles, Corrine I. Voils, D. Ryan Anderson, Amanda Eudy, Rebecca E. Sadun, Jennifer L. Rogers, Lisa G. Criscione-Schreiber, Jayanth Doss, Mithu Maheswaranathan, Megan Clowse
The Journal of Rheumatology Sep 2022, jrheum.220399; DOI: 10.3899/jrheum.220399